AlloVir Management
Management criteria checks 3/4
AlloVir's CEO is Diana Brainard, appointed in May 2021, has a tenure of 3.58 years. total yearly compensation is $6.06M, comprised of 10.3% salary and 89.7% bonuses, including company stock and options. directly owns 0.31% of the company’s shares, worth $166.84K. The average tenure of the management team and the board of directors is 5.9 years and 4.4 years respectively.
Key information
Diana Brainard
Chief executive officer
US$6.1m
Total compensation
| CEO salary percentage | 10.3% |
| CEO tenure | 3.6yrs |
| CEO ownership | 0.3% |
| Management average tenure | 5.9yrs |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely
Oct 29
Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely
Jul 13We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully
Feb 09Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Oct 03Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Jun 23Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?
Mar 02Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?
Nov 11AlloVir GAAP EPS of $0.69 beats by $1.42
Aug 04AlloVir stock surges on $126.6M securities offering
Jul 27Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?
Jul 27Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Mar 21AlloVir: A Comparative Study Of Its Manufacturing Process
Feb 07We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate
Nov 02AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues
Oct 02AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price
Aug 06We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth
Jul 01AlloVir EPS misses by $0.08
May 06AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans
Apr 01This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)
Feb 07Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?
Jan 08FDA clears AlloVir's ALVR106 application in respiratory viruses
Dec 17Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data
Dec 07We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth
Dec 04
AlloVir EPS misses by $0.28
Nov 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$100m |
| Jun 30 2024 | n/a | n/a | -US$140m |
| Mar 31 2024 | n/a | n/a | -US$180m |
| Dec 31 2023 | US$6m | US$623k | -US$190m |
| Sep 30 2023 | n/a | n/a | -US$169m |
| Jun 30 2023 | n/a | n/a | -US$167m |
| Mar 31 2023 | n/a | n/a | -US$166m |
| Dec 31 2022 | US$9m | US$605k | -US$169m |
| Sep 30 2022 | n/a | n/a | -US$189m |
| Jun 30 2022 | n/a | n/a | -US$192m |
| Mar 31 2022 | n/a | n/a | -US$185m |
| Dec 31 2021 | US$15m | US$365k | -US$172m |
| Sep 30 2021 | n/a | n/a | -US$139m |
| Jun 30 2021 | n/a | n/a | -US$117m |
| Mar 31 2021 | n/a | n/a | -US$91m |
| Dec 31 2020 | US$597k | n/a | -US$70m |
Compensation vs Market: Diana's total compensation ($USD6.06M) is above average for companies of similar size in the US market ($USD650.00K).
Compensation vs Earnings: Diana's compensation has been consistent with company performance over the past year.
CEO
Diana Brainard (53 yo)
3.6yrs
Tenure
US$6,056,943
Compensation
Dr. Diana M. Brainard, MD., served as an Entrepreneur Partner at MPM Asset Management, L.L.C. since 2024. She served as an Executive Partner and Entrepreneur at MPM Asset Management, L.L.C. till December 2...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 6.3yrs | US$347.00k | 2.46% $ 1.3m | |
| CEO & Director | 3.6yrs | US$6.06m | 0.31% $ 166.8k | |
| President | 5.9yrs | US$2.94m | 0.85% $ 463.2k | |
| General Counsel & Secretary | 5.9yrs | US$1.89m | 0.38% $ 203.6k | |
| Chief Accounting Officer | 5.9yrs | no data | 0.012% $ 6.7k | |
| Chief Scientific Officer | 11.9yrs | no data | no data |
5.9yrs
Average Tenure
55.5yo
Average Age
Experienced Management: ALVR's management team is seasoned and experienced (5.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 6.3yrs | US$347.00k | 2.46% $ 1.3m | |
| CEO & Director | 4.4yrs | US$6.06m | 0.31% $ 166.8k | |
| President | 5.9yrs | US$2.94m | 0.85% $ 463.2k | |
| Member of the Scientific Advisory Board | 1.8yrs | no data | no data | |
| Independent Non-Executive Director | 12.9yrs | US$196.28k | 0.20% $ 108.6k | |
| Independent Non-Executive Director | 4.4yrs | US$211.78k | 0.066% $ 35.7k | |
| Member of Scientific Advisory Board | 1.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.8yrs | no data | no data | |
| Independent Non-Executive Director | 5.6yrs | US$209.28k | 0.057% $ 30.9k | |
| Independent Director | 2.8yrs | US$200.73k | 0% $ 0 | |
| Non-Executive Director | 10.9yrs | US$187.00k | 2.08% $ 1.1m |
4.4yrs
Average Tenure
58yo
Average Age
Experienced Board: ALVR's board of directors are considered experienced (4.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 07:05 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AlloVir, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Zemansky | BofA Global Research |
| Anupam Rama | J.P. Morgan |
| Mani Foroohar | Leerink Partners LLC |